Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Withdraws Q2, FY 2020 Guidance Due to COVID-19 Impact

NEW YORK – Agilent Technologies announced that it is withdrawing its second-quarter and fiscal year 2020 guidance due to the global impact of COVID-19 on its business activities.

While the firm's Q2 revenues rose 2 percent through March, it noted a significant disruption in business activity in late March, especially in the US and Europe, as customers closed or restricted access to their facilities in an attempt to slow the spread of the coronavirus.

Agilent previously expected revenues of $1.28 billion to $1.32 billion and adjusted EPS of $.72 to $.76 for the second quarter. For the fiscal year 2020, the firm had expected revenues of $5.5 billion to $5.55 billion and adjusted EPS of $3.38 to $3.43.

Despite implementing measures to minimize expenses, Agilent said it is unable to reasonably estimate the speed of recovery in its end markets nor the related impact on financial results for the remainder of the financial year.

The firm will provide additional details during its Q2 earnings conference call scheduled for May 21.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.